Brexit

Brexit: Artwork Challenges for Pharma Industry

March 4, 2019 Artwork Pack Management, Pharmaceutical, Regulatory Affairs

The impact of Brexit is evident in almost every industry based in the European Union (EU) and the United Kingdom (UK). Pharmaceutical industry too not to be spared.

Read More
Brexit: The MHRA and The Proposed eSubmission Portal

February 18, 2019 Publishing & Submissions

The impact of Brexit has been a major topic for debates amongst the industry experts for the past two years. It has left companies on both the sides, the United Kingdom (UK) and Europe, hanging on a loose thread. As the date of Brexit is drawing closer, industries are aggressively looking for contingency plans for sustaining their business, if the UK leaves with a ‘no-deal’.

Read More
2019 and Farther – A Regulatory Heads-up

January 7, 2019 Medical Devices, Nutraceuticals/Food Supplements, Pharmaceutical, Regulatory Affairs

With each year, Life Sciences industry is transforming in unpredictable ways, of course it is to better the end-user’s safety. The industry is progressing with technological advancements and the health authorities are equally striving to upgrade the existing Regulatory frameworks to align with market requirements.

Read More
ISO Revises Implementation Guidelines for ISO 11238

September 5, 2018 Pharmaceutical

As the Brexit transformation and transitions are in full pace, the European Medicines Agency (EMA) is firm on releasing periodical updates for implementation of the Identification of Medicinal Products (IDMP).

Read More
Brexit and its Possible Impact on the UK Life Sciences Industry

November 17, 2016 Artwork Pack Management, Regulatory Labeling, Health Authority Updates

If the latest government figures are any witness, the United Kingdom Life Sciences industry is a thriving £60 billion market, employing 220,000 people, and any potential threat to its growth is quite understandably worrisome.

Read More
The Brexit and the aftermath

June 30, 2016 Regulatory Intelligence, Regulatory Labeling, Regulatory Consulting, Health Authority Updates

The impact on Regulatory ecosystems in the UK and EU

Is it the time to be alert for drug and medical device manufacturers associated with the European Union (EU) and the United Kingdom (UK)? As Britain voted to leave the EU, the situation seems to be uncertain for drug/pharmaceutical companies to plan ahead with the regulatory processes, at least for a while into the future.

Read More